文摘
摘要目的:我们的目标是确定静脉注射的安全性和有效性tPA患者基底动脉动脉治疗机械血栓切除术。
背景:的结合静脉组织纤溶酶原激活物(IV-tPA)和机械血栓切除术(MT)的前循环一直在研究大型随机临床试验。然而,数据的安全性和有效性IV-tPA结合太为基底动脉动脉是有限的。
设计/方法:pc搜索业务是连续的多中心回顾性注册病人太为基底动脉闭塞2015年7月- 2021年12月。病人从注册表被包括在这项研究中,如果他们提出医院4.5小时内出现症状。记录变量包括基线特征、过程数据,影像学和临床结果。良好的临床结果被定义为≤3夫人在90天。多元逻辑回归模型来确定预测良好的临床结果。
结果:共有519名患者参加了pc搜索业务注册的218个病人来到医院在4.5小时的演讲。IV-tPA管理到99(45%)的患者。基线人口统计变量包括年龄,性别,和基线风险因素是相似的两组之间除了低署(16.5和18.1;p = 0.05)和更频繁的历史之前的中风IV-tPA组(26.1% vs . 10.1%;p = 0.002)。PC-ASPECTS,成功的血管再通,死亡率,和良好的临床结果(43.7% vs . 49.5%;p = 0.38)也在两组之间的比较。多变量分析表明IV-tPA之前太不是一个预测结果在90天(可信区间0.81 - 3.71或1.74;p = 0.16)。
结论:患者基底动脉动脉,IV-tPA政府之前太似乎安全但不影响临床结果在90天。进一步的研究是必要的。
披露:Afreen博士没有披露。Mierzwa博士没有披露。扎伊迪博士没有披露。Gharaibeh博士没有披露。Aladamat博士没有披露。萨米艾尔卡萨伯没有披露。纳尔逊博士没有披露。奥尔特加古铁雷斯博士已经收到个人薪酬在10000 - 49999美元的范围为stryker担任顾问。奥尔特加古铁雷斯博士已经收到个人薪酬在10000 - 49999美元的范围为美敦力公司担任顾问。奥尔特加古铁雷斯博士已经收到个人薪酬在5000 - 9999美元的范围为microvention担任顾问。 Dr. Ortega Gutierrez has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for SVIN. The institution of Dr. Ortega Gutierrez has received research support from stryker. The institution of Dr. Ortega Gutierrez has received research support from Siemens. The institution of Dr. Ortega Gutierrez has received research support from IschemiaView. The institution of Dr. Ortega Gutierrez has received research support from Medtronic. Dr. Farooqui has nothing to disclose. Mr. Vivanco-Suarez has nothing to disclose. Dr. Jadhav has nothing to disclose. Dr. Desai has nothing to disclose. Dr. Toth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dynamed. Dr. Toth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Microvention. Dr. Toth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Alrohimi has nothing to disclose. Dr. Nguyen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vesalio. Dr. Nguyen has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Nguyen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avania. Dr. Nguyen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AHA. The institution of Dr. Nguyen has received research support from Boston Medical Center. The institution of Dr. Nguyen has received research support from Society of Vascular and Interventional Neurology. Mr. Klein has nothing to disclose. Mohamad Abdalkader has nothing to disclose. Dr. Pandey has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NIH and SVIN- Journal. Dr. Pandey has stock in FlexDex. Dr. Pandey has stock in NextGen. The institution of Dr. Pandey has received research support from NIH. The institution of Dr. Pandey has received research support from Focused ultrasound foundation. Dr. Pandey has received intellectual property interests from a discovery or technology relating to health care. Sravanthi Koduri has nothing to disclose. Vora Shivangi has nothing to disclose. Nirav Vora has nothing to disclose. Dr. Jumaa has nothing to disclose. Dr. Salahuddin has nothing to disclose.
